The 5th International Workshop – GBHI 2022 will be held on September 28 – 29, 2022 in Amsterdam, The Netherlands.
The Global Bioequivalence Harmonisation Initiative is intended to support the process of global harmonization via scientific discussion among international stakeholders. Therefore, a series of international conferences was founded by EUFEPS in collaboration with AAPS supported from the beginning by the European Medicines Agency (EMA) as well as the U.S. Food and Drug Administration (FDA). Regulators and speakers from other countries/regions, e.g., Canada, Chile, China, India, Japan, Jordan, Mexico, and Brazil, will be invited to the discussions. Such global participation presents an ideal platform for scientists from regulatory agencies, pharmaceutical industry and academia to exchange their experience and scientific viewpoints: scientific consensus should constitute the most appropriate basis for harmonization. The Organising Committee of the 5th GBHI Workshop is now presenting the topics, date and venue of the next conference. After the 4th conference in Washington in 2019, now Amsterdam has again been selected as the location.
Amsterdam welcomes you in September 2022!
Amsterdam is unique among the European metropolises. Compared to other world cities, Amsterdam is quite small, but it offers all the advantages of a metropolis – a multitude of historical sights, world-famous museums and a distinctive nightlife. The city itself has an international flair and offers something for every taste. Nothing is far apart and everything is well served by public transport.
The topics are as follows:
- Fed vs fasted studies for immediate release dosage forms: relevance of excipients, disintegration/dissolution specificities, drug substance properties and physiological GI conditions – new findings shall help achieve harmonisation
- Statistical considerations for BE assessment: replicate design for BE of Highly Variable Drugs, two-stage design and PK modelling as supportive tools for BE assessment
- Topical products: Scientifically-based approaches for a waiver of clinical endpoint trials
- Narrow therapeutic index drugs: study design and acceptance criteria For more information see the detailed program.
